Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 6/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | TP53 | P04637 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | HTR2B | P41595 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | HTR2C | P28335 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 5/20 | 0.55 |
| ▸ | NPC1 | O15118 | 5/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9400692 | 0.99 | HTR2C (0.57) | ATRMEN1KMT2AMAPTTP53 | |
| SCHEMBL31668675 | 0.84 | NPC1 (0.64) | MAPTRAB9ANPC1MAOAMAOB | |
| SCHEMBL22803696 | 0.84 | NPC1 (0.67) | MAPTRAB9ANPC1MAOAMAOB | |
| SCHEMBL6166855 | 0.83 | MAOA (0.73) | MAPTRAB9ANPC1MAOAMAOB | |
| SCHEMBL8523959 | 0.83 | RAB9A (0.71) | ATRMEN1KMT2AMAPTLMNA | |
| SCHEMBL31668688 | 0.83 | MAOA (0.66) | MAPTRAB9ANPC1MAOAMAOB | |
| SCHEMBL22803697 | 0.82 | KDM4E (0.60) | ATRMEN1KMT2AKDM4ERAB9A | |
| SCHEMBL8789974 | 0.82 | FGFR2 (0.49) | ATRMAPTKDM4ERAB9ANPC1 | |
| SCHEMBL1743495 | 0.79 | IMPDH2 (0.69) | MEN1KMT2AMAPTTP53KDM4E | |
| Hydrochloric Acid SCHEMBL18321794 | 0.79 | MEN1 (0.58) | MEN1KMT2AMAPTTP53KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5328922-A | Anxiolytic and antidepressant activity | BEECHAM GROUP P.L.C. (GB) | 1994-07-12 | — | — | US | claimed |
| WO-1993018026-A1 | INDOLE UREAS AS 5-HT1C RECEPTOR ANTOGONISTS | BEECHAM GROUP PLC (GB) | 1993-09-16 | — | — | WO | claimed |
| WO-1993016694-A1 | USE OF INDYLPYRIDYLUREAS TO HEAL THE EFFECTS OF BRAIN OR SPIRAL TRAUMA | SMITHKLINE BEECHAM PLC (GB) | 1993-09-02 | — | — | WO | claimed |
| EP-0550507-A1 | INDOLE UREAS AS 5 HT RECEPTOR ANTAGONIST | Beecham Group p.l.c. (GB) | 1993-07-14 | — | — | EP | claimed |
| WO-1992005170-A1 | INDOLE UREAS AS 5 HT RECEPTOR ANTAGONIST | BEECHAM GROUP PLC (GB) | 1992-04-02 | — | — | WO | claimed |
| US-20220193082-A1 | COMBINATION TREATMENT OF SPECIFIC FORMS OF EPILEPSY | ZOGENIX INTERNATIONAL LIMITED (GB) | 2022-06-23 | — | — | US | disclosed |
| US-20170071949-A1 | COMBINATION TREATMENT OF SPECIFIC FORMS OF EPILEPSY | ZOGENIX INTERNATIONAL LIMITED (GB) | 2017-03-16 | — | — | US | disclosed |
| WO-1993016694-A1 | USE OF INDYLPYRIDYLUREAS TO HEAL THE EFFECTS OF BRAIN OR SPIRAL TRAUMA | SMITHKLINE BEECHAM PLC (GB) | 1993-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220193082-A1 | COMBINATION TREATMENT OF SPECIFIC FORMS OF EPILEPSY | HTR2B, HTR3B, HTR5A | ATR 2991/4885MEN1 919/4885KMT2A 726/4885 |
| US-20170071949-A1 | COMBINATION TREATMENT OF SPECIFIC FORMS OF EPILEPSY | HTR2B, HTR3B, HTR5A | ATR 2991/4885MEN1 919/4885KMT2A 726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.